Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
9 LDP Leader Candidates Showcase Pharma Agendas in Campaign
Nine legislators have announced their bid for the Liberal Democratic Party’s (LDP) presidential election scheduled for September 27. While the poll’s hot topics are the fund scandals involving party factions and whether to allow separate surnames for married couples, multiple…
To read the full story
Related Article
- Kamikawa Runs for LDP Presidency, Resolved to Empower Healthcare Realm
September 12, 2024
- Ex-Minister Kato Joins Fray in LDP Race, Pledges Inflation-Linked Drug Prices
September 11, 2024
- Takaichi Vows to Bolster Japan’s Self-Sufficiency of Drugs, Vaccines in LDP Race
September 11, 2024
- Kobayashi Declares Bid for LDP Race, Urges More Investment in Pharma
August 20, 2024
REGULATORY
- Japan Approves Takeda’s Orzeyful, Insmed’s Brinsupri and More Drugs
August 25, 2026
- Japan Grants Orphan Tags to Rogocekib, Gildeuretinol, and More
August 25, 2026
- Japan Extends Re-Examination Period for Uplizna
August 25, 2026
- 4 Drug Makers Seek Govt Aid to Upgrade Aging Plants: LDP Hearing
August 24, 2026
- 679 Safety Reports Logged for Regenerative Medical Products in 2H FY2025
August 21, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…